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Treatment of chronic pain in oncology: 
cooperation between the oncologist  
and psychooncologist
ABSTRACT
The aim of this work is to present the problem of chronic pain in neoplastic disease as a situation requiring dia­
gnosis and interdisciplinary treatment. The phenomenon of chronic pain, its types, and causes are discussed. 
A discussion was held on appropriate scales for measuring pain intensity. Pharmacotherapy and psychotherapy 
were primarily presented among the discussed treatment methods, and issues related to other methods of inter­
actions related to the treatment of patients with chronic pain in the course of neoplastic disease were discussed. 
The key aspect of the article is to draw attention to the implementation of multi­specialist treatment of chronic 
pain, including personalised solutions and the accommodation of the most favourable form of therapy and the 
methods of its implementation.
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Introduction
The incidence of cancer is constantly growing both 
in the world and in Poland. Malignant neoplasms are 
the second cause of death in Poland after cardiovascular 
disease. It is estimated that one in four people will die 
from cancer [1]. In more than half of patients cancer is 
in an advanced stage at the time of diagnosis and is as-
sociated with the presence of clinical symptoms.
In addition to anti-cancer therapy the proper diag-
nostics and treatment of pain is one of the key aspects 
of oncological care. 
Literature data show that during radical treatment, 
as many as 30–50% of patients experience pain, and 
in advanced stages this problem affects over 80% of 
patients [2].
Pain should be considered as a psychosomatic phe-
nomenon, which is defined as a subjective, multi-area 
experience that is individually felt by the person. Ac-
cording to the International Association for the Study 
of Pain (IAPS) and the World Health Organisation 
(WHO), pain is “an unpleasant sensory and emotional 
sensation caused by actual or potential tissue dam-
age”. This definition includes sensory (related to pain 
perception) as well as emotional components (related 
to mental reactions to a given painful stimulus). The 
emotional component is subjective and, as mentioned 
earlier, it has an individual dimension for a given 
patient [3, 4].
The following factors characterise pain as a holis-
tic experience:
 — physiological symptoms of pain (physical dimen-
sion);
 — the impact of pain on the patient’s functioning and 
self-care activities (functional dimension);
 — the impact of pain on emotions as well as the quantity 
and quality of social relations (the psychosocial di-
mension);
 — understanding the meaning of suffering, purpose of 
life, worldview, life attitudes (spiritual dimension);
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 — history of pain experiences, current experience of 
pain, anxiety problems, adaptation to cancer (be-
havioural dimension) [4].
Pain is a manifestation of cancer, occurring at various 
stages of disease, starting from being the first symptom 
of the developing disease (primary tumour or metas-
tases), pain occurring during anti-cancer treatment 
(oncological surgery, chemotherapy, radiotherapy, and 
others), up to pain at the end-stage of the disease. Pain 
can also occur during remission or in cured patients as 
a consequence of previous causal treatment [5, 6]. The 
results of a meta-analysis conducted in 2016 and based on 
the data from over 66,000 people showed that 39.3% of 
people experienced pain associated with the treatment, 
55% suffered from pain during cancer treatment, and 
66.4% suffered from pain in the advanced, metastatic, 
or terminal phase of the disease [7]. Scientific analyses 
performed in the last two decades suggest an improve-
ment in the pharmacological adequacy of analgesic 
therapy. However, almost 30% of patients still do not 
receive analgesics adequately to the intensity of pain [8].
In the current, 11th version of the International Clas-
sification of Diseases (ICD), chronic pain is defined as 
persistent (continuous) or recurrent (intermittent, epi-
sodic) for more than three to six months. It does not play 
the role of warning physiological nociception in acute 
conditions. It is estimated that chronic pain affects about 
20% of people worldwide [6]. In response to this issue, 
new categories of chronic have pain emerged, including:
 — chronic primary pain;
 — chronic cancer pain;
 — chronic post-traumatic and post-operative pain;
 — chronic neuropathic pain;
 — chronic headache and mouth and facial pain;
 — chronic visceral pain;
 — chronic musculoskeletal pain [6].
Types and causes of cancer pain
The Polish Society for the Study of Pain (PTBB) 
classifies pain in cancer according to the cause and 
distinguishes the following types of pain:
 — pain caused by the presence of primary tumour/metastases;
 — pain caused by the diagnosis and treatment of cancer;
 — pain syndromes indirectly related to cancer or not 
related to oncological disease;
 — breakthrough pain [9].
In turn, the European Society for Clinical Oncology 
(ESMO), among the causes of non-tumour-related pain, ad-
ditionally distinguished pain occurring in convalescents [10]. 
Cancer pain can also be categorised by the type of 
ailments: neuropathic pain (non-receptor, pathologi-
cal) and nociceptive pain (receptor), which consists of 
somatic and/or visceral pain [10]. 
Pain caused by the presence  
of a tumour
The pain caused by the presence of the tumour is 
usually mixed and consists of several types of pain with 
different pathomechanisms (i.e. neuropathic, somatic, 
and visceral). 
Somatic pain affects 70–80% of patients with exist-
ing tumour mass and it may be the result of irritation 
of nerve endings (nociceptors) or lowering their excit-
ability threshold in the case of inflammation around 
tumour tissues and consequent release of inflammatory 
mediators (e.g. prostaglandins, histamine, bradykinin) 
[11, 12]. Somatic pain derives from bones, joints, mus-
cles, skin, or connective tissue. Pain from soft tissues is 
the result of occlusion of blood and/or lymph vessels by 
the tumour and infiltration of soft tissues and serous 
membranes. On the other hand, bone pain arises from 
the invasion of the bone marrow by the tumour, which 
leads to an increase in intraosseous pressure, periosteal 
distension, and proliferation of nerve fibres in the bone 
marrow and periosteum as a consequence of nerve 
growth factor (NGF) activity. Metastases in the bones 
can cause local or root pain [9]. Somatic pain is acute 
pain, strictly located, which increases in direct propor-
tion to the deterioration of the local condition [13]. 
Visceral pain caused by the presence of a tumour 
occurs in 30% of patients [11]. It is described by patients 
as aching, colic, and diffuse pain. Visceral pain arises 
in the organs of the digestive system due to stretching 
of the organ’s capsule, compression or pulling through 
the tumour tissue of ligaments, blood vessels, mesentery, 
pleura, or peritoneum. Inflammatory mediators, as in 
the pathomechanism of somatic pain, can stimulate vis-
ceral nociceptors. In addition, infiltration of nerve fibres 
and vessels that supply visceral organs is responsible for 
the development of diffuse pain [9, 11].
Neuropathic pain due to tumour expansion occurs in 
30–40% of patients and shows paroxysmal and stabbing 
features [11]. It is accompanied by breakthrough pain, 
that is short and very strong. It can also be characterised 
by generalised dysaesthesia, hyperalgesia, and allodynia. 
Depending on primary tumour or metastases location 
neuropathic pain is divided into peripheral or central. 
Neuropathic pain is the result of pressure or damage of 
peripheral nerves or nerve plexuses. Peripheral nerve 
injury is a signal for the parent’s neuron body in the 
spinal ganglia to activate gene expression and produc-
tion of protein particles transported to the site of injury. 
As a result of biochemical changes, new receptors are 
formed, which are the source of stimuli responsible for 
the formation of paroxysmal pain. In addition, nerve 
damage leads to pathological synaptic connections be-
tween different types of nerve fibres, contributing to the 
incorrect sensation of stimuli (analogous to allodynia, hy-
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peralgesia, dysaesthesia) [12]. In addition, neuropathic 
pain occurs in paraneoplastic syndromes (e.g. peripheral 
sensory polyneuropathy, Lambert-Eaton myasthenic 
syndrome [LEMS], paraneoplastic myopathy, cerebellar 
degeneration, paraneoplastic encephalitis) [9]. 
Pain caused by diagnostics and 
anticancer treatment
Approximately 20% of cancer patients experience 
iatrogenic pain caused by chemotherapy, radiotherapy, 
hormone therapy, corticosteroid therapy, targeted 
therapy, or surgery [9–11]. Iatrogenic pain is usually 
neuropathic in nature because it is the result of nerve 
damage, leading to defective perception of pain in the 
peripheral or central nervous system [13].
Peripheral neuropathies are most often caused by 
the use of anti-cancer neurotoxic drugs (vincristine, 
vinblastine, vinorelbine, paclitaxel, docetaxel, platinum 
derivatives). Neuropathic pain after cytotoxic drugs is 
often described by patients as tingling, numbness, sting-
ing, or stabbing pain. During hormone therapy with 
antioestrogens and aromatase inhibitors, side effects 
may appear in the form of osteoarticular pain [10].
Granulocyte colony-stimulating factors (G-CSF) 
most commonly induce bone pain during chemotherapy 
[9]. However, as a result of high doses of corticosteroids 
in premedication for chemotherapy or symptomatic 
treatment during palliative care, there is a risk of de-
veloping painful inflammatory changes of the skin and 
oral mucosa, infection, peripheral neuropathy, sterile 
osteonecrosis (Calve’s, Legg’s, and Perthes’ disease), 
osteoporosis, and osteonecrosis [9, 10, 13].
Surgical procedures may result in damage of the 
peripheral nerves and consequently persistent pain after 
mastectomy, thoracotomy, phantom pain, stump pain. 
In turn, radiotherapy can lead to fibrosis of the brachial 
or lumbar plexuses, myelopathy, and radiation-induced 
necrosis. In addition, radiotherapy is responsible for 
the occurrence of chronic inflammation of the mucous 
membranes of the mouth, throat, oesophagus, intestines, 
and anus [9, 10].
In addition to pain of iatrogenic origin, there are 
also — often overlooked — pain complaints associated 
with the diagnosis and invasive procedures, developed 
by the ESMO classification of non-tumour-related pain, 
distinct categories for iatrogenic pain and severe proce-
dural pain. Acute pain syndrome may be a complication 
after puncture, biopsy, endoscopy, angiography, and 
other diagnostic interventions [10].
Pain in convalescents is another, separate category of 
pain symptoms defined by the ESMO. It may be a con-
sequence of procedures performed as part of observa-
tion or persistent side effects of the therapies used [10]. 
An example of a group of patients particularly exposed 
to persistent iatrogenic pain are women after radical 
surgical treatment due to breast cancer and supplemen-
tary chemotherapy with paclitaxel and radiotherapy to 
the chest wall area.
Other pain syndromes in cancer 
patients
The category of other pain syndromes most often 
concerns ailments unrelated to cancer and anticancer 
treatment (e.g. diabetic neuropathy, fibromyalgia, 
angina pectoris, tension and migraine headaches, 
osteoarthritis, Herpes virus infection and subsequent 
postherpetic neuralgia, acute thrombotic syndromes, 
immobilisation leading to activation of trigger points 
and myofascial complaints, and others). The used 
anti-cancer treatment may in these situations deepen 
the pre-existing pain [9, 10].
Breakthrough pain
Breakthrough pain is an episodic and transient ex-
acerbation of pain in patients successfully treated with 
opioids due to cancer pain. The Polish Society for the 
Study of Pain (PTBB) divides pain into three categories:
 — spontaneous pain caused by unknown aetiologi-
cal factors;
 — incidental pain, which may be voluntary (e.g. when 
attempting to move) or involuntary (e.g. colic pain);
 — procedural pain that arises during care, diagnostic, 
or rehabilitation procedures [9].
Breakthrough pain, regardless of the cause, is charac-
terised by a rapid increase in the severity of pain (on aver-
age up to 10 min) and short duration (up to about 50 min).
Pain assessment
An inseparable element of effective analgesia is clini-
cal pain assessment, including the location, migration, 
nature (quality), intensity, and mitigating factors, pain 
intensity, efficacy and tolerance of previous treatment, 
and the occurrence of breakthrough pain. These factors 
allow us to determine the pathomechanism (type) of 
pain. An important element of pain assessment is also 
the evaluation of the mental component [9].
The use of appropriate analgesia should be preceded 
by an accurate interview and assessment of pain, using 
formal, validated assessment tools. Due to the complex-
ity of the nature of cancer pain and attempts to classify it, 
no uniform, universally binding classification of cancer 
pain has been determined [2].
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The most popular and useful tool recommended for 
the assessment of pain intensity is the NRS (Numerical 
Rating Scale). It is a 10-point numerical scale in which 
0 means no pain, 1–3 (up to 4) means mild pain, 4–6 (up 
to 7) moderate pain, 7–8 strong pain, and 9–10 very 
strong pain. The patient evaluates the pain intensity by 
indicating the number characterising his/her pain sensa-
tion. This scale is a standardised tool and is used not only 
to assess the intensity of pain, but also the effectiveness 
of treatment. Effective analgesic treatment is when the 
severity of pain measured by the NRS scale is ≤ 3 [2, 9].
Another method enabling descriptive assessment 
of pain intensity is the Verbal Rating Scale (VRS), 
available in two versions, i.e. either four-stage: no pain, 
weak, moderate, and severe pain, or five-stage Likert 
version: no pain, weak, moderate, strong, and unbear-
able pain [2]. 
The NRS (numerical) scale is more sensitive in 
comparison to the VRS (verbal) scale; hence, its use 
in clinical practice and scientific analyses is recom-
mended [9, 14].
Among the available pain assessment tools, there are 
also image scales (e.g. with facial expressions defining 
the current state and dedicated mainly to children and 
people with impaired contact). The next scale is the 
PHHPS (Prince Henry Hospital Pain Score) used to 
assess the severity of pain at rest and during movement. 
It is used in people with postoperative pain [14].
The exact assessment of pain should not be based 
solely on the evaluation of its intensity but should also 
include a qualitative assessment of pain and its impact 
on the patient’s functioning. For this purpose, the Brief 
Pain Inventory (Short Form), the Pain Assessment 
Sheet, the McGill Pain Questionnaire, and the Dolo-
plus scale are used. In some patients, the test should 
include an additional assessment of touch, pricking, 
pressure, temperature difference, vibration, and time 
summation. This mainly applies to patients with a neu-
ropathic component of pain. Throughout the treatment 
period, it is necessary to constantly monitor analgesia 
and vital signs. In recent years, different new forms of 
screening tools have been developed to facilitate the 
diagnosis of neuropathic pain, clarify its character, and 
implement appropriate treatment. It is emphasised 
that a reliable measurement of pain intensity should 
be based on more than one method [16]. An example 
of additional methods may be the DN4 questionnaire 
(Douleur Neuropathique 4 Questions), PainDETECT 
Questionnaire, LANSS (Leeds Assessment of Neuro-
pathic Symptoms and Sings), or NPQ (Neuropathic Pain 
Questionnaire). On the basis of the Delphi analysis, the 
use of the DN4 scale is particularly recommended for 
the assessment of neuropathic pain [9, 15]. 
To assess the severity of pain and its control, it 
may be useful to propose to the patient that they keep 
a so-called diary of pain. The patient can use different 
forms of expressing his/her feelings written in the table 
or in another way (e.g. by using a verbal description or 
marking on a scale from 1 to 10 an appropriate number 
defining his/her pain sensation or drawing a face sym-
bolising the appropriate level of pain sensations). The 
table can also have an extended version, in which the 
patient records all information about taken medicines 
(date, time, medicine, its effectiveness, and others). The 
mentioned form may additionally support the diagnostic 
and therapeutic process [17].
Psychological reactions to pain
It is well recognised that pain is perceived in the 
physical (somatic) mental, social, and spiritual dimen-
sions. The pain caused by cancer, regardless of its stage, 
has a negative impact on the patient’s quality of life, and 
a low quality of life contributes to an increase of sensiti-
vity to pain and reduces tolerance to pain. Chronic pain, 
due to its long duration, contributes to the reduction of 
physical, professional, and social activity [4].
The deterioration of the quality of life of people 
with chronic pain is also affected by physiological, 
psychological, and social disorders. This is not directly 
related to the aetiology of pain, but closely correlates 
with the duration and intensity of pain. Chronic pain 
consequently prevents people from carrying out 
professional tasks, contributes to the limitation and 
weakening of social contacts, and even worsening of 
functioning in life roles. Patients develop a sense of 
hopelessness and negative emotional states, which 
may result in depression and anxiety [4]. It was found 
that in the course of cancer the risk of mood and 
anxiety disorders increases, affecting 47% of cancer 
patients. The most frequently diagnosed include the 
following: adaptive (32%), depressive (6%), and iso-
lated anxiety disorders (2%) [2].
Treatment of pain
Pharmacotherapy
Pharmacological treatment of cancer pain is based 
on WHO recommendations according to the so-called 
three-stage analgesic ladder.
The first stage of the analgesic ladder
Stage I drugs include non-opioid analgesics for 
low-intensity pain (1–4 on the NRS scale according 
to PTBB) and bone pain [9, 10]. This group includes 
NSAIDs, paracetamol, and metamizole. Paracetamol 
is safer than NSAIDs and it is recommended by PTBB 
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as the first choice analgesic in low-intensity pain [9]. In 
cancer pain with an inflammatory component (includ-
ing bone pain), NSAIDs are recommended [9, 10]. In 
addition, non-opioid analgesics may also be used in 
breakthrough pain in some situations [9]. If the cause of 
neuropathic pain is nerve compression without perma-
nent damage to the nervous tissue, anti-inflammatory 
drugs can be beneficial. In the case of permanent nerve 
damage, NSAIDs are ineffective [18].
As a result of intensive treatment, side effects 
characteristic for individual groups can occur. Each 
side effect increases the suffering of cancer patients 
and worsens the quality of life. Side effects of NSAIDs 
include the following: gastric mucosa damage, gastro-
intestinal bleeding, as well as liver and kidney damage. 
Special care should be taken in elderly people due to 
the severity of heart and kidney failure. In addition, 
NSAIDs increase the risk of myocardial infarction and 
ischaemic stroke, even if used within a short period of 
time [17]. Metamizole used in colic and breakthrough 
pain can cause bone marrow damage. An overdose of 
paracetamol may result in liver damage [13].
The second stage of the analgesic ladder
Drugs of the second stage of the analgesic ladder are 
so-called weak opioids, used for moderate pain (4–6 on 
the NRS scale according to PTBB). This group includes 
tramadol, codeine, and dihydrocodeine [9, 10]. They 
are used in the case of ineffectiveness of drugs of the 
first level of the WHO analgesic ladder. Weak opioids 
are characterised by a ceiling effect — exceeding the 
maximum dose does not increase analgesia, but only 
increases the risk of side effects [18]. Tramadol is the 
recommended first-choice drug of the second stage of 
the analgesic ladder [9]. It should be remembered, how-
ever, that the analgesic activity of tramadol is depend-
ent on the CYP2D6 enzyme; therefore, in people not 
metabolising the substrates of this enzyme, the analgesic 
effect is weaker. In addition, care should be taken in the 
elderly and in patients with epileptic seizures, because 
tramadol decreases the seizure threshold. It should not 
be used concomitantly with antidepressants due to the 
risk of serotonergic syndrome [9, 10].
Opioids have an additional antitussive and anti-
diarrhoeal effect, reducing the severity of additional 
symptoms of cancer [13]. Codeine and dihydrocodeine 
can be used in patients with pain of moderate intensity 
accompanied by cough. It should be remembered that 
codeine induces severe side effects (especially in young 
people) and is not the preferred drug according to PTBB 
recommendations [9]. In the case of long-term use of 
opioid drugs, some patients may experience persistent 
constipation and nausea and vomiting. When starting 
opioid use, antiemetics should be recommended for the 
first 5–7 days and laxatives [9]. 
On the second stage of the analgesic ladder the 
small doses of the so-called strong opioids (i.e. mor-
phine 30 mg orally daily, oxycodone 20 mg orally daily, 
hydromorphone 4 mg orally daily) can be also used [9]. 
There is no evidence of increased side effects of this 
treatment regimen compared to the use of so-called 
weak opioids [10].
According to PTBB and ESMO recommendations, 
weak and strong opioids should not be combined [9, 10].
The third stage of the analgesic ladder 
Drugs of the third stage (so-called strong opioids 
— e.g. fentanyl, morphine, tapentadol, oxycodone, 
hydromorphone, buprenorphine, methadone) are used 
in the case of ineffectiveness of drugs from previous 
groups. Morphine, oxycodone, hydromorphone should 
be the first-line drugs for the treatment of moderate to 
severe pain (6–10 on the NRS scale) [9, 10].
In addition to the analgetic effect morphine also 
reduces the feeling of dyspnea. The advantages of 
morphine in the treatment of patients with cancer pain 
are: no ceiling effect and the possibility of application 
in any form (oral, subcutaneous, intravenous, rectal, 
transmucosal, epidural, subarachnoid, and locally on 
skin and mucous membranes affected by disease). In 
cancer patients receiving morphine in analgesic doses 
in symptomatic treatment, respiratory depression is 
rare because pain is a strong agonist to the respiratory 
centre. In general, morphine is recommended in the 
oral form, and in patients with swallowing problems, 
the subcutaneous form should be used [9, 11, 13]. 
Morphine in intravenous form should be administered 
to people with massive peripheral oedema, coagulation 
disorders, and poor peripheral circulation. Morphine 
and oxycodone should not be used in patients with 
renal insufficiency due to the reduced elimination of 
metabolites [9, 10]. 
According to the recommendations of PTBB, oxy-
codone or oxycodone with naloxone should be the first 
choice in the treatment of cancer pain with a visceral 
component. In addition, oxycodone is an appropriate 
medicine for neuropathic pain [9, 10].
Fentanyl is used as a transdermal system, and in 
breakthrough pain it also works in sublingual, nasal, and 
buccal form. The biggest threat with its use is associated 
with drug accumulation and strong physical and mental 
addiction. Percutaneous forms are not suitable for the 
treatment of patients with unstable pain and fever [9, 
18]. However, it should be remembered that in patients 
with breakthrough pain a first-choice analgetic should be 
an oral drug in an immediate release formulation, while 
the use of transmucosal fentanyl should be secondary. 
The dose of the drug in breakthrough pain should be 
15–20% of the daily dose of the parent drug or another 
opioid after dose conversion [9, 10]. 
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Buprenorphine is 75 times more potent than mor-
phine; it is characterised by significant lipophilicity and is 
used primarily in the transdermal form. Buprenorphine 
as well as fentanyl and methadone can be safely used in 
chronic renal disease with GFR < 30 mL/min [9, 10]. 
Buprenorphine is the first-choice drug in the elderly 
and in patients with liver failure [9]. It can be used in 
a sublingual form in breakthrough pain.
Methadone is applicable when other strong opioids 
are ineffective or when their side effects occur [9, 10, 18].
Hyperalgesia is a usual side effects of all opioids. This 
is a paradoxical reaction with pain intensification when 
using opioid drugs. The mechanism is not well under-
stood, it is thought that it may be a genetic basis for 
opioid receptors. In the case of hyperalgesia to a specific 
opioid, switching to another drug also from the opioid 
group is recommended. A dose reduction of opioid caus-
ing hyperalgesia and adding of coanalgesics is a scheme 
less recommended by PTBB [9].
Coanalgesic adjuvants 
The typical analgetic drugs, which can be added 
on each stage of the analgesic ladder, include coan-
algesics or coanalgesic adjuvants. Supportive therapy 
usually refers to neuropathic or bone pain. This group 
includes — among others — corticosteroids, anticon-
vulsants (carbamazepine, gabapentin), local anaesthet-
ics, calcitonin, cannabinoids and antidepressants (e.g. 
tricyclic antidepressants — amitriptyline, doxepin, 
nortriptyline, desipramine and tetracycline antidepres-
sants — mirtazapine, serotonin reuptake inhibitors 
— escitalopram, citalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline, serotonin and epinephrine 
reuptake inhibitors — venlafaxine, duloxetine, mil-
nacipran). The mechanism of action of antidepressants 
consists of inhibition of NMDA receptors or inhibition 
of noradrenaline/serotonin reuptake from the synaptic 
cleft, contributing to the intensification of nociception 
inhibition. The use of coanalgesics is helpful in treating 
the accompanying symptoms in oncological disease and 
chronic pain: insomnia, anxiety, and depression [9, 11].
Psychotherapy and other  
non-pharmacological methods
Psychotherapy is used in various dysfunctions and 
diseases, including as a complementary treatment meth-
od to pharmacotherapy in cancer patients with chronic 
pain. Over the last three decades Cognitive Behavioural 
Therapy (CBT) has been mainstreamed and has become 
a recommended psychotherapy method. Evidence of 
its effectiveness in pain problems and comprehensive 
pain syndromes is confirmed by numerous randomised 
studies. CBT is the main method dedicated to patients 
with pain and can be used alone or in combination with 
medical methods in an interdisciplinary aspect. Impor-
tantly, it is used in the treatment of all types of chronic 
pain, not only cancerous [19, 20].
Numerous studies show that strong pain fosters 
a growing sense of threat and ruminating and induces the 
conviction of an inability to cope with it, which is associ-
ated with the occurrence of physical and psychosocial 
disorders (even after controlling pain and reducing the 
level of depression). There are a lot of questions in the 
analyses regarding the occurrence of mood, anxiety, and 
sleep disorders in many people struggling with chronic 
pain, in which CBT could be applicable [19, 20].
The main goal of psychotherapy is to reduce the 
feeling of pain and mental suffering and to improve the 
physical and role functions. This is achieved by working 
on the change of “maladaptive” behaviours, increas-
ing adaptive behaviour, identifying and correcting 
“maladaptive” thoughts and beliefs, as well as increasing 
self-effectiveness in coping with pain [19, 20].
There is no standard algorithm or procedure for 
analgesic treatment using psychotherapy in the CBT 
paradigm. The time devoted to the clinical diagnosis, 
evaluation, and number of sessions and therapeutic 
techniques used is individual and diverse. The most 
commonly used techniques include relaxation training, 
setting and working towards behavioural goals (usu-
ally involving systematic increase in physical activity 
and other activities), behavioural activation, activity 
stimulation tips, problem-solving education, and cogni-
tive restructuring. Typically, in cognitive-behavioural 
therapy, there are exercises between therapeutic 
sessions to train and apply new skills (e.g. thought 
recording, relaxation practice, work on behavioural 
goals) [17, 19, 20].
The effectiveness of CBT in the treatment of chronic 
pain has been confirmed by meta-analyses and numer-
ous opinions, which, however, emphasise the role of 
CBT as part of the therapeutic program alongside 
pharmacotherapy and the patient’s own work [19, 20].
Among other methods supporting the process of 
pain treatment, one should mention hypnosis, which acts 
by lowering distress (demotivating — harmful stress), 
and relaxation and meditation methods. An important 
method is psychoeducation, which is designed to educate 
patients of understanding and ways of communicating 
the problems related to pain, anxiety, and depressed 
mood. The effect of psychoeducation is to increase the 
sense of self-efficacy and certainty as to the ability to 
deal with it. Research results indicate that education, 
hypnosis, relaxation, and visualisation support the ac-
quisition of stress management skills and, independently 
of analgesics, may reduce the intensity of pain. These 
effects are so significant that they should be considered 
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Figure 1. Interdisciplinary treatment of chronic pain. Own elaboration based on literature included in the bibliography
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— Relaxation and breathing 
    techniques
— Visualisation
— Complementary methods 
(e.g. massage, physical 
therapy, acupuncture, 
biofeedback, meditation)
I
NON-OPIOID ANALGESICS:
— Metamizole
— NSAIDs
SPASMOLYTICS:
— Drotaverine
— Buscolysin
— Psychoeducation
— Occupational therapy
— Music therapy
— Complementary methods 
(e.g. massage, physical 
therapy, acupuncture, 
biofeedback, meditation)
NRS 1–4
NRS 4–7
NRS 7–10
NON-OPIOID ANALGETICS:
— Paracetamol
— NSAIDs
ANTIEPILEPTIC DRUGS
ANTIDEPRESSANT DRUGS
— SNRIs
— TCAs
— Psychoeducation
— Occupational therapy
— Music therapy
— Complementary methods 
(e.g. massage, physical 
therapy, acupuncture, 
biofeedback, meditation)
WEAK OPIOIDS
— Tramadol
STRONG OPIOIDS 
IN LOW DOSES:
— Oxycodone
— Morphine
ANTIEPILEPTIC DRUGS
ANTIDEPRESSANT DRUGS
LIDOCAINE IN AN 
INTRAVENOUS INFUSION
— Psychoeducation
— Psychotherapy
— Hypnosis
— Relaxation and breathing 
    techniques
— Visualisation
— Complementary methods 
(e.g. massage, physical 
therapy, acupuncture, 
biofeedback, meditation)
STRONG OPIOIDS:
— Oxycodone
— Morphine
— Fentanyl
— Tapentadol
— Buprenorphine
— Methadone
ANTIEPILEPTIC DRUGS
ANTIDEPRESSANT DRUGS
LIDOCAINE IN AN 
INTRAVENOUS INFUSION
BOTULIN TOXIN
NEUROLYSIS
NEUROMODULATION
— Psychoeducation
— Psychotherapy
— Hypnosis
— Relaxation and breathing 
    techniques
— Visualisation
— Complementary methods 
(e.g. massage, physical 
therapy, acupuncture, 
biofeedback, meditation)
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as the standard elements of care for patients treated for 
cancer pain [17, 20, 21].
It is undeniable that psychological factors contrib-
ute to an increase in the pain and suffering experienced 
by the patient. However, knowledge about the aetiol-
ogy of pain and methods of optimal coping with it are 
insufficient, and questions about which strategies are 
the most effective for which pain syndromes remain 
unanswered. There is a need for professional integra-
tion of people with specialist knowledge in the field of 
pain treatment, at both the medical and psychological 
levels [19–21].
Issues regarding the treatment of pain and care 
of patients at the request of the Polish Society for the 
Study of Pain were legally enshrined in the amendment 
to the Law on Patients’ Rights and the Patient’s Rights 
Ombudsman of May 11, 2017. In Chapter 6, art. 20, 
p. 13 we can read: 
“1.  The patient has the right to pain treatment. 
  2.  The entity providing health services is obliged to take 
actions to determine the degree of pain intensity, treat 
pain, and monitor the effectiveness of this treatment”.
According to the aforementioned, it is the duty of 
the medical personnel not only to apply the treatment 
in connection with the underlying disease, but also to 
conduct the treatment in connection with the accom-
panying painful ailments. Therefore, the patient has 
the right to require appropriate analgesics from every 
doctor and health care facility [22].
Summary
Pain is a phenomenon and experience not only 
physical but also emotional, psychosocial, and spiritual. 
In connection with the perception of psychological and 
existential needs related to pain, the necessity to sup-
plement therapeutic procedures has arisen. According 
to this idea, the treatment of chronic pain in the course 
of cancer cannot be limited to pharmacological treat-
ment alone, and psychotherapeutic methods should 
not be treated as an addition or as an alternative to 
pharmacological treatment of pain. Figure 1 presents 
a proposal for the treatment of chronic pain, in which, 
on the basis of the analgetic ladder, pharmacological and 
non-pharmacological methods of pain therapy according 
to its intensity and aetiology are presented (divided into 
visceral and neuropathic pains). Supportive methods 
were considered such as physiotherapy, visualisation 
techniques, relaxation techniques, crisis interventions, 
methods using art and music, desensitisation, and 
others. Coanalgesics or additional agents (e.g. bispho-
sphonates, denosumab, or glucocorticosteroids and 
non-pharmacological treatment techniques — localised 
radiotherapy, radioisotopes in multifocal pain, percu-
taneous TENS nerve electrical stimulation, epidural or 
spinal analgesia, and others) should be a complement.
One should always take an individual approach to 
therapeutic interactions based on the patient’s needs and 
personal features. It is necessary to take into account 
the purpose of such therapy, consisting of increasing 
the sense of pain control and significantly improving 
patients’ quality of life. These procedures should also 
focus on psychosocial support and provide appropriate 
education for the families and relatives of the patient. 
The above activities increase the patient’s sense of con-
trol and reduce the level of helplessness of caregivers 
and family. Pharmacological treatment is commonly 
insufficient and can be associated with a multitude of 
side effects or a lack of therapeutic effects. Integrated 
treatment of people with chronic pain will significantly 
reduce its level or completely eliminate it, which in turn 
will translate into restoring the patient’s will to continue 
their lives and give them strength to deal with the dis-
ease. Achieving success on this basis is associated with 
the necessity of close cooperation between oncologist 
and a psychooncologist or psychologist, preferably at 
the level of a multidisciplinary team (MDT).
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